CONCLUSION
A temporary reduction in the incidence of RCC and especially early stage RCC should be expected as a result of the decrease in the frequency of incidentally detected RCC due to the decline in hospital admissions during the COVID-19 pandemic, stay-at-home orders, postponement of all non-emergency surgeries, and the fact that healthcare professionals were busy managing the pandemic. However, a proportional increase in the rate of symptomatic patients and metastatic patients should be expected in this period due to recommendations for patients experiencing concerning symptoms to continue applying to hospitals. After the COVID-19 pandemic, it is possible to encounter higher rates of advanced stage RCCs and metastatic RCCs. Since the COVID-19 pandemic is still ongoing and its end cannot be predicted, the importance of early surgical treatment should be kept in mind by comparing the risk-benefit ratio in cancers such as RCC that have high metastasis rates at the time of diagnosis and after curative surgery.